Avoid concomitant utilization of tucatinib with CYP3A substrates, where by minimum concentration improvements could bring about really serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose In accordance with solution labeling. withdrawal reactions, which includes seizures, that may be lifetime-threatening; use gradual taper when discontinuing therapy to r... http://galenika diazepam 10mg